Recombinant human antibody to Human TNFRSF10A. Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody for the treatment of cancer.
Figure 1 Mapatumumab and etoposide synergize to induce apoptosis through the mediation of NF-jB.
(A) Inhibition of NF-jB disrupts synergy between Mapatumumab and etoposide. HT29 cells were untreated, treated with 100 lM etoposide, 10 lM BAY 11-7082, or 100 ug/ml of Mapatumumab alone or in combination. 48 h after treatment cells were collected and cell death was assessed by acridine orange staining. Error bars represent the standard deviation of three independent experiments. Statistical significance was calculated using a Student's t test. (B) Combination treatment between Mapatumumab and Etoposide increases DNA fragmentation; this is disrupted by NFjB blockage. Cells were treated with 100 uM etoposide, 10 lM BAY 11-7082, 100 ug/ml of Mapatumumab, or 20 uM of z-VAD-FMK alone or in combination. 48 h after transfection cells were collected and stained with propidium iodide staining buffer.
Mendoza, F. J., Ishdorj, G., Hu, X., & Gibson, S. B. (2008). Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment. Apoptosis, 13(6), 756.
Figure 2 Cleaved caspase-8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.
Immunoprecipitation (IP) assays of mapatumumab (Mapa) or lexatumumab (Lexa) were conducted in LP1, MDN, and NCI-H929 cells. Cells (20 × 106) were incubated with or without (control) 10 μg/mL of mapatumumab (45 minutes) or lexatumumab (90 minutes) at 37°C in RPMI-1640 containing 5% FCS. For NCI-H929, cells were pretreated for 2 hours with 2.5μmol/L nutlin-3a (N) before addition of lexatumumab. The lysates were immunoprecipitated with a mix of proteins A and G (2 mg of lysate proteins were immunoprecipitated in each assay). For untreated cells, IP was conducted after addition of mapatumumab or lexatumumab to the lysates. The immunoprecipitates were analyzed for the presence of the indicated proteins by immunoblot (IB) analysis. Input, lysates of untreated or treated cells; Ct Ip< IP of control lysates (untreated cells); Ip< IP of lysates obtained from cells treated with mapatumumab or lexatumumab. *, heavy chain of mapatumumab or lexatumumab.
Surget, S., Chiron, D., Gomez-Bougie, P., Descamps, G., Ménoret, E., Bataille, R., ... & Pellat-Deceunynck, C. (2012). Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer research, canres-0487.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-TNFRSF10A ADCC Recombinant Antibody (Mapatumumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human TNFRSF10A. Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody for the treatment of cancer.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-160CQ | Human Anti-TNFRSF10A Recombinant Antibody (TAB-160CQ) | ELISA, FC | Human IgG |
TAB-160CQ-S(P) | Human Anti-TNFRSF10A Recombinant Antibody; scFv Fragment (TAB-160CQ-S(P)) | ELISA, FC | Human scFv |
TAB-160CQ-F(E) | Human Anti-TNFRSF10A Recombinant Antibody; Fab Fragment (TAB-160CQ-F(E)) | ELISA, FC | Human Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-161CQ | Anti-Human TNFRSF10A Recombinant Antibody (4H6.17.8) | FC, ELISA, Block | |
TAB-161CQ-S(P) | Anti-Human TNFRSF10A Recombinant Antibody scFv Fragment (4H6.17.8) | ELISA, FC, BL | |
TAB-162CQ-S(P) | Anti-Human TNFRSF10A Recombinant Antibody scFv Fragment (4E7.24.3) | ELISA, FC, BL | |
TAB-161CQ-F(E) | Anti-Human TNFRSF10A Recombinant Antibody Fab Fragment (4H6.17.8) | ELISA, FC, BL | |
TAB-162CQ-F(E) | Anti-Human TNFRSF10A Recombinant Antibody Fab Fragment (4E7.24.3) | ELISA, FC, BL |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-2090MZ | Recombinant Mouse Anti-Human TNFRSF10A Antibody (clone 43B353) | WB | Mouse antibody |
HPAB-651-FY | Human Anti-TNFRSF10A Recombinant Antibody (HPAB-651-FY) | ELISA, FC, Agonist | Human IgG |
HPAB-0412-YJ | Mouse Anti-TNFRSF10A Recombinant Antibody (HPAB-0412-YJ) | ELISA, FuncS, FC | Mouse IgG |
HPAB-0413-YJ | Human Anti-TNFRSF10A Recombinant Antibody (HPAB-0413-YJ) | ELISA, FuncS, FC | Chimeric (Mouse/Human) IgG1 |
HPAB-S0144-YC | Human Anti-TNFRSF10A Recombinant Antibody (clone ch4H6) | ELISA, FC, Block, ADCC | Chimeric (mouse/human) IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-2109CQ | Mouse Anti-TNFRSF10A Recombinant Antibody (clone 32A1380) | FC, IHC, Neut, WB | Mouse IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-4466 | Rabbit Anti-TNFRSF10A Recombinant Antibody (clone SI560DS) | ELISA | Rabbit IgG |
MOR-4467 | Rabbit Anti-TNFRSF10A Recombinant Antibody (clone SI561DS) | FC | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0627-CN | Camelid Anti-TNFRSF10A Recombinant Antibody (HPAB-0627-CN) | ELISA | VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-651-FY-S(P) | Human Anti-TNFRSF10A Recombinant Antibody; scFv Fragment (HPAB-651-FY-S(P)) | ELISA, RIA | Human scFv |
HPAB-J0290-YC-S(P) | Human Anti-TNFRSF10A Recombinant Antibody (clone 7.1.3); scFv Fragment | FC, Apop, Inhib, FuncS | Human scFv |
HPAB-J0291-YC-S(P) | Human Anti-TNFRSF10A Recombinant Antibody (clone 7.3.2); scFv Fragment | FC, Apop, Inhib, FuncS | Human scFv |
HPAB-J0292-YC-S(P) | Human Anti-TNFRSF10A Recombinant Antibody (clone 7.12.2); scFv Fragment | FC, Apop, Inhib, FuncS | Human scFv |
HPAB-S0144-YC-S(P) | Human Anti-TNFRSF10A Recombinant Antibody (clone ch4H6); scFv Fragment | ELISA, FC, Block, ADCC | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-H48 | Afuco™ Anti-TNFRSF10A ADCC Recombinant Antibody (Mapatumumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0412-YJ-F(E) | Mouse Anti-TNFRSF10A Recombinant Antibody; Fab Fragment (HPAB-0412-YJ-F(E)) | ELISA, FuncS | Mouse Fab |
HPAB-0413-YJ-F(E) | Human Anti-TNFRSF10A Recombinant Antibody; Fab Fragment (HPAB-0413-YJ-F(E)) | ELISA, FuncS | Human Fab |
HPAB-1616-FY-S(P) | Mouse Anti-TNFRSF10A Recombinant Antibody (clone mAY4); Fab Fragment | WB, ELISA | Mouse Fab |
HPAB-1617-FY-S(P) | Human Anti-TNFRSF10A Recombinant Antibody (clone hAY4); Fab Fragment | WB, ELISA | Humanized Fab |
HPAB-1618-FY-S(P) | Human Anti-TNFRSF10A Recombinant Antibody (clone Hvh3); Fab Fragment | WB, ELISA | Human Fab |
There are currently no Customer reviews or questions for TAB-H48. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.